Smith & Nephew outsources 140 jobs; CardioMEMS heart monitoring device gets add-on payment from CMS;

@FierceMedDev: Cohera's surgical adhesive narrowly wins FDA panel support. Article | Follow @FierceMedDev

@StacyALawrence: Smith & Nephew touts acquisitions, offers bulk hospital buying. Story | Follow @StacyALawrence

@VarunSaxena2: ICYMI: FDA announces intention to comprehensively regulate lab-developed tests. Article | Follow @VarunSaxena2

@MichaelGFierce: Nature-inspired artificial cilia could help move drugs to a target. Story | Follow @MichaelGFierce

@EmilyWFierce: Small, portable telemedicine device conducts 33 Dx tests and could improve health monitoring in India. More from Quartz India | Follow @EmilyWFierce

> Smith & Nephew ($SNN) is moving 140 jobs in its advanced wound management unit from the U.K. to China. Article

> St. Jude's ($STJ) recently acquired CardioMEMS heart failure monitoring device received a New Technology Add-on Payment from the Centers for Medicare and Medicaid Services, in recognition of its innovative features. Release

> A device that can conduct 33 medical tests has the potential to save lives in emerging markets like India by detecting conditions like eclampsia, a disorder that leads to convulsions or coma during pregnancy. Article

Pharma News

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Article | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Impax 0-2 in inspection double header. FDA issues another Form 483 at Hayward, after spanking Taiwan plant. More | Follow @EricPFierce

@CarlyHFierce: GSK private eyes' son allowed first visit to parents in China jail as trial nears. Article | Follow @CarlyHFierce

> Note to Big Pharma: Discounts work. GSK price cuts score Advair a payer boost. Story

> Hep C a rare disease? Drugs from Gilead, J&J, et al. could make it so, but at a price. Item

> Novo Nordisk more valuable than GlaxoSmithKline? That's what investors say. Report

> Is Medicare wasting $220M a year on Questcor's controversial Acthar? More

> Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. News

Biotech News

@FierceBiotech: ICYMI yesterday: Roche's pRED buys out Santaris in $450M RNA acquisition. Article | Follow @FierceBiotech

@JohnCFierce: So, Juno has now raised more than $300M in less than 12 months. Why not go public while they're at it? Release | Follow @JohnCFierce

@DamianFierce: A lot of money: Juno has raised more than $300M in a year to develop a promising new approach to cancer treatment. More | Follow @DamianFierce

> Japanese researcher found dead amid a swirling stem cell research scandal. More

> How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article

> Mapp Bio stays mum during Ebola media storm. Item

> Insmed shares shrivel as PhIII Arikayce plan chills hopes for quick OK. Story

Biotech Research News

> Experimental vaccine for C. difficile successful in animal models. Report

> Mice without regulator protein show longer life, fewer tumors. More

> Senate bill would set NIH budget floor, raise funding over 7 years. Article

> Scripps researchers uncover new signaling pathway in brown fat cells. Story

> Peptide measurement predicts Ebola deadliness. Item

Pharma Manufacturing News

> Tough FDA oversight pushing some API makers to look for U.S. expansion. Item

> Novartis' U.S. Diovan plant gets 'For Sale' sign. Article

> FDA piles misery onto Impax with 2nd Form 483 in a week. News

> Labor disputes lead Pfizer to lock workers out of plant in India. Story

> Glenmark to invest $17 million in production facilities in North Carolina. Article

And Finally... After more than 80 years, Bayer has decided to give up the neon sign atop Mt. Washington in Pittsburgh, which owner Lamar Advertising says will go to a new, yet unnamed client. Story

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.